ArticleInternational journal of colorectal disease2025
Assessment of the correlation between visceral adiposity and liver fat in metastatic colorectal cancer patients.
Article in International journal of colorectal disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe study aims to evaluate the correlation between visceral adiposity, fatty liver, and survival in patients with metastatic colorectal cancer (mCRC).
methodsThe study included 131 adult patients with treatment-naive mCRC. The visceral and liver fat content was measured using baseline computed tomography (CT) images. The analysis used the 50th percentile (131.80 HU) visceral adiposity value as a cutoff. The visceral and liver fat content association with patient characteristics and outcomes was assessed.
resultsIn the overall cohort, neither visceral adiposity (median OS 37.8 vs 36.7 months, HR = 0.83; p = 0.428) nor liver steatosis (median OS 46.0 vs 33.9 months, HR = 0.81; p = 0.370) showed significant association with OS. However, in patients with BMI ≥ 25 kg/m
conclusionWe observed a possible association between liver steatosis and OS in patients with mCRC in the high BMI subgroup. Prospective studies are essential to validate these findings and the role of liver steatosis in the prognostic assessment of mCRC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.